About J-TEC
J-TEC is a publicly listed company based in Gamagori (Japan) founded in 1999. Regenerative medical products are developed using tissue engineering technology. It operates on a Professional Services and HealthTech model. The company has 204 employees. Its website jpte.co.jp draws about 18 thousand monthly visits. J-TEC offers products and services including Regenerative Medicine Products, Regenerative Medicine Contract Services, and Cultured Human Tissue Products. Its focus areas include Biotechnology and Regenerative Medicine. Its legal entity is Japan Tissue Engineering Co., Ltd.
Company details
Japan Tissue Engineering Co., Ltd., known as J-TEC, is focused on regenerative medicine. The company is involved in the development and provision of regenerative medicine products, contract services for regenerative medicine developers, and cultured human tissue products for research purposes. Operations are centered in the healthcare and biotechnology sectors, with an emphasis on making regenerative medicine a standard medical practice. Efforts are also made to ensure product reliability and safety. Sustainability and ethical considerations are integrated into the business through initiatives like the J-TEC Ethics Committee.
- Headquarters Gamagori, Japan
- Employees 204
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website jpte.co.jp/english
- Legal Name Japan Tissue Engineering Co., Ltd.
- Annual Revenue$13.67 M (USD)-11.11as on Mar 31, 2026
- Net Profit-$4.61 M (USD)-187.79as on Mar 31, 2026
- EBITDA-$2.5 M (USD)-220.01as on Mar 31, 2026
- Employee Count204
Products & Services of J-TEC
J-TEC offers a comprehensive portfolio of products and services, including Regenerative Medicine Products, Regenerative Medicine Contract Services, and Cultured Human Tissue Products.
Products for regenerative medicine are developed and provided.
Contract services for regenerative medicine are offered professionally.
Human tissue products for research are manufactured and supplied.
IPO & Listings of J-TEC
J-TEC is a publicly listed company on the TSE with ticker symbol 7774 in Japan, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2013
- Listed onTSE: 7774
- Listed entityJapan Tissue Engineering Co., Ltd.
- Exchange sectorHealth services
- ISINJP3389610001
- Share price789.00 JPY (-1.5% on the day) · 2026-10-14
- Market capitalisation32,528,573,822.00 JPY
- EPS (diluted, trailing year)-10.84 JPY
- Volume (last session)35,800
Financials of J-TEC
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.18B JPY | -734.8M JPY | -399.2M JPY |
| 2024 | 2.46B JPY | -255.3M JPY | -124.7M JPY |
| 2023 | 2.51B JPY | 143.2M JPY | 242.3M JPY |
| 2022 | 2.03B JPY | -729.3M JPY | -596.7M JPY |
| 2021 | 2.10B JPY | -497.9M JPY | -373.2M JPY |
Detailed financial statements for J-TEC
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of J-TEC
The website of J-TEC (jpte.co.jp) receives about 18.4K visits a month and ranks #1,129,717 among all websites worldwide, #1,398 in Biotechnology and Pharmaceuticals.
- Monthly visits18.4K
▲ 15.7% vs previous month
- Unique visitors6.6K
per month
- Global rank#1,129,717
among all websites
- Category rank#1,398
Health · Biotechnology and Pharmaceuticals
- Bounce rate52%
- Pages per visit4.6
- Average visit3 min 11 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with J-TEC. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
saiseiiryo.jp | saiseiiryo.jp | 100% | #2,324,645 | – | |
| pss.co.jp | 86% | 12.2K | #2,048,926 | View details | |
| cellseed.com | 84% | 22.5K | #1,450,872 | View details | |
nippongene.com | nippongene.com | 84% | #792,891 | – | |
| kringle-pharma.com | 84% | 2.5K | #2,077,026 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 34 similar websites and full traffic analytics for J-TEC
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about J-Tec
Complete news archive for J-TEC
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about J-TEC
J-TEC was founded in 1999.
J-TEC is headquartered in Gamagori, Japan. It is registered at Gamagori, Aichi, Japan.
J-TEC has 204 employees.
Annual revenue of J-TEC is $13.67M as on Mar 31, 2026.
Japan Tissue Engineering Co., Ltd., known as J-TEC, is focused on regenerative medicine. The company is involved in the development and provision of regenerative medicine products, contract services for regenerative medicine developers, and cultured human tissue products for research purposes. Operations are centered in the healthcare and biotechnology sectors, with an emphasis on making regenerative medicine a standard medical practice. Efforts are also made to ensure product reliability and safety. Sustainability and ethical considerations are integrated into the business through initiatives like the J-TEC Ethics Committee.
J-TEC offers Regenerative Medicine Products, Regenerative Medicine Contract Services, and Cultured Human Tissue Products.
Yes, J-TEC is publicly traded on TSE under the ticker symbol 7774.
J-TEC operates through Japan Tissue Engineering Co., Ltd..